NASDAQ : CGON
CG Oncology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 63.47 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.63B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.73B |
| Enterprise Value | 4.71B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 88.64M |
| Shares Outstanding | 88.64M |
| Shares Change (YoY) | +14.15% |
| Shares Change (QoQ) | +4.36% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 94.38% |
| Float | 68.28M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 920.56 |
| Forward PS | 462.71 |
| PB Ratio | 5.55 |
| P/TBV Ratio | 5.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 756.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 22.22 |
| Quick Ratio | 21.78 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.41% |
| Return on Assets (ROA) | -17.67% |
| Return on Invested Capital (ROIC) | -18.47% |
| Return on Capital Employed (ROCE) | -24.33% |
| Weighted Average Cost of Capital (WACC) | 6.16% |
| Revenue Per Employee | $43,859 |
| Profits Per Employee | -$1.58M |
| Employee Count | 142 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +50.49% |
| 50-Day Moving Average | 69.43 |
| 200-Day Moving Average | 65.90 |
| Relative Strength Index (RSI) | 49.12 |
| Average Volume (20 Days) | 858,522 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.87M |
| Short Previous Month | 10.44M |
| Short % of Shares Out | 10.01% |
| Short % of Float | 13.00% |
| Short Ratio (days to cover) | 8.13 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.23M |
| Gross Profit | -161.54M |
| Operating Income | -252.62M |
| Pretax Income | -224.38M |
| Net Income | -224.38M |
| EBITDA | -249.66M |
| EBIT | -252.62M |
| Loss Per Share | -$2.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 8.82M |
| Net Cash | 1.02B |
| Net Cash Per Share | $11.50 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 11.65 |
| Working Capital | 1.00B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -178.47M |
| Capital Expenditures | -876,000 |
| Depreciation & Amortization | 2.96M |
| Net Borrowing | n/a |
| Free Cash Flow | -179.34M |
| FCF Per Share | -$2.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -4,056.18% |
| Pretax Margin | -3,602.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.15% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.21% |
| FCF Yield | -3.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $91.08 |
| Price Target Difference | 40.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 359.04% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 41.42 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |